• What You Should Know about Tymlos (Abaloparatide) for Osteoporosis
    May 20, 2017
    By Caila Brander, NWHN Policy Fellow There’s a new kid in town when it comes to osteoporosis drugs. Meet abaloparatide, brand name Tymlos, which was approved by the FDA on April 28, 2017. If you haven’t heard of it yet, you likely will soon, as manufacturer Radius Health is intent on marketing it until it’s also ...
  • Trumpcare and the Return of Rape and Domestic Violence as Pre-existing Conditions
    May 16, 2017
    Recent history demonstrates that even strong state protections may be insufficient in practice to help survivors of rape, sexual assault, or domestic violence. On May 6, the Washington Post published a disconcerting piece denying that the House-passed Trumpcare bill would ultimately lead to discrimination against victims of rape, sexual assault, or domestic violence. Even the headline ...
  • The Trumpcare #zombiebill is back!
    April 27, 2017
      Like the zombie in a bad horror movie that keeps rising, again and again, the Trumpcare bill to repeal the Affordable Care Act (ACA) is once again threatening our health care. With Donald Trump’s 100th day in office just two days away, the media-obsessed White House has been in a panic to notch a win—even ...
  • NWHN Shines a Spotlight on Scott Gottlieb – Why He is Wrong for Women!
    April 4, 2017
    This Wednesday, the Senate Committee on Health, Education, Labor and Pensions (HELP) will consider the nomination of Dr. Scott Gottlieb to head the Food and Drug Administration (FDA) with a floor vote possible at the end of April. Gottlieb has made millions of dollars consulting for and investing in the pharmaceutical industry and continues to be ...
  • Weighing Your Options: Depo-Provera and HIV Risk!
    March 31, 2017
    By Caila Brander, NWHN Policy Fellow Researchers studying the link between contraceptive use and HIV have uncovered a connection between using the Depo-Provera and contracting HIV. In light of these findings, the World Health Organization (WHO) has changed its safety classification for injectable contraception. Depo-Provera is the most widely used injectable contraception around the world, and ...
  • Ending the Endometriosis Silence
    March 24, 2017
    The 4th annual Worldwide Endometriosis March will take place on March 25th. Endometriosis is a chronic disease that affects women during their reproductive years. It occurs when uterine-lining tissue is found growing outside of the uterus, typically resulting in immense pain during and between periods, heavy and long menstrual cycles, gastrointestinal upsets, and fatigue. There ...
  • The ACA Turns 7 Today! What Has It Meant for Women?
    March 23, 2017
    Today we celebrate the seventh anniversary of the Patient Protection and Affordable Care Act (ACA), the biggest leap forward for women’s health in a generation. Those first two words of the law’s name are often dropped for convenience but as we reflect on everything the law has done, it’s important to remember that “patient protection” ...
  • Why Insurance Doesn’t Work Like a Salad Bar
    March 16, 2017
    By Caila Brander, NWHN Policy Fellow One of the most controversial debates stemming from Republican efforts to repeal the Affordable Care Act (ACA) has been over maternity coverage and who should pay for it. Under the ACA, coverage for maternity and newborn care—like coverage for mental health care, prescription drugs, and more—is part of the essential ...
  • The Best Defense is a Good Offense: Get Tested!
    March 9, 2017
      For 12 years, March 10 has been observed as National Women and Girls HIV/AIDS Awareness Day (NWGHAAD). The CDC estimates that over 280,000 women are living with HIV and of those women, 11% don’t know they are infected. The theme for NWGHAAD is: The Best Defense is a Good Offense. This theme speaks volumes because ...
  • Birth Control is More Effective When Providers Empower Women!
    March 6, 2017
    By Caila Brander, NWHN Policy Fellow The Guttmacher institute recently published a report that concluded that birth control failure rates are decreasing across the country, after years of stagnated progress. Every method presented a gap between how well it works if used exactly how it is intended to be used, versus its“typical-use” failure rate, which measures ...